BERLIN -- Adding durvalumab (Imfinzi) to bacillus Calmette-Guérin (BCG) induction and maintenance therapy significantly ...

To kick things off, we'll set the stage on what defines non-muscle invasive bladder cancer and how we triage patient ...

A phase 2 trial evaluated the combination of neoadjuvant pembrolizumab and accelerated methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy in patients with nonurothelial bladder cancers ...

This is the first meta-analysis comparing the overall survival of patients with limited-stage small cell bladder cancer who underwent radical surgery with platinum-based perioperative chemotherapy vs ...

The BladderPath trial indicates that mpMRI can expedite MIBC treatment and improve bladder cancer-specific survival compared to traditional TURBT. The study showed a significant improvement in BCSS ...

Bipolar transurethral resection represents a significant evolution in the surgical management of bladder cancer, particularly for non‐muscle invasive bladder cancer (NMIBC). This technique utilises an ...

EORTC GUCG 2418 - STARBURST: Strategies for treatment adaptation following re-evaluation of the bladder after using primary neoadjuvant systemic therapies—An EORTC platform trial. This is an ASCO ...

Bladder cancer is one of the most common urological cancers, with nonmuscle invasive forms accounting for a significant portion of new diagnoses. In September, UC Davis Comprehens ...

The addition of Tecentriq to BCG therapy did not significantly improve outcomes for patients with non–muscle-invasive bladder ...

CatalYm, a world-leader in neutralizing GDF-15 in cancer and cachexia, today presented compelling primary results from the ...

Analysis of Tumor Microenvironmental Features Between Primary and Synchronous Liver Metastases From Patients With Colorectal Cancers Using a Deep Learning Algorithm We present an automated tumor risk ...

CAPS Medical, a clinical-stage MedTech company developing a platform for selective tumor ablation across multiple indications ...